Clinical Trial Update: Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating pyrotinib combined with metronomic capecitabine in HER2-positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN